Ascendis Pharma AS (ASND) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN DK0060615755
Ascendis Pharma AS financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 363.64 m EUR | 691.71 m EUR |
| Gross profit | 319.38 m EUR | 588.53 m EUR |
| Operating income | -278.76 m EUR | -130.89 m EUR |
| EBIT | -307.74 m EUR | -126.79 m EUR |
| Net income | -378.08 m EUR | -219.03 m EUR |
| Diluted EPS – continuing operations | -6.53 EUR | -3.61 EUR |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
More stocks
- Zhejiang Century Huatong Group Co Ltd (002602.SZ)
- Korea Electric Power Corp ADR (KEP)
- Pan Pacific International Holdings Corp (7532.T)
- Trimble Inc. (TRMB)
- Sieyuan Electric Co Ltd (002028.SZ)
- Topicus.com Inc (TOI.V)
- Elia Group SA (ELI.BR)
- OMEGA HEALTHCARE INVESTORS INC (OHI)
- Cemex SAB de CV ADR (CX)
- ARC Resources Ltd (ARX.TO)
- Stanley Black & Decker (SWK)
- Uni-President Enterprises Corp (1216.TW)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.